MARLBOROUGH, Mass.,
April 20, 2017 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
clinical-stage RNAi company developing innovative therapeutics that
address significant unmet medical needs, today announced that it
will present new data from the Company's consumer product
development program, based on its proprietary self-delivering RNAi
(sd-rxRNA®) technology, at the Society for Investigative
Dermatology (SID) 76th Annual Meeting. The SID
mission is to advance and promote the sciences relevant to skin
health and disease through education, advocacy and scholarly
exchange of scientific information. This annual meeting is being
held April 26-29, 2017 at the
Oregon Convention Center in
Portland Oregon.
- Topical Application of Self-delivering RNAi (sd-rxRNA)
Compounds for Reduction of Hyperpigmentation
RXI-231: sd-rxRNA Targeting Tyrosinase (TYR)
This poster will show that reduction of tyrosinase mRNA levels by
sd-rxRNA in cultured cells leads to a decrease in visible
pigmentation and melanin content, in line with the expected
mechanism of action of an RNAi compound. In addition, as
demonstrated ex vivo in pig skin, our proprietary
formulation allows for the non-invasive penetration of sd-rxRNA
compounds to the epidermal dermal junction where TYR-producing
melanocytes reside. Consumer testing will initiate in
May 2017.
Date and Time: April 29, 2017
10:15 AM PDT
Presented by: Melissa
Maxwell
Session 3: Pigmentation and Melanoma
Poster #: 810, Exhibit Hall A
- Prevention of UVR Induced MMP1 Upregulation with an MMP1
Targeting Self-delivering RNAi (sd-rxRNA) Compound May Reduce the
Effects of Skin Photo-aging
RXI-185: sd-rxRNA
Targeting Collagenase (MMP1)
Results from a collaboration with DSM, one of the industry's
leading suppliers of ingredients and innovative solutions for
beauty care products, will be presented. This poster will
show that RXI-185 is capable of reducing MMP1 mRNA levels and
enzyme activity in cultured human dermal fibroblasts and in an
in vitro human skin model after UVR-induced MMP1
upregulation. In addition, Fl-RXI-185 is capable of reducing
MMP1 mRNA levels following topical administration in an ex
vivo human skin model.
Date and Time: April 29, 2017
10:15 AM PDT
Presented by: Katherine
Holton
Session 3: Photobiology
Poster #: 756, Exhibit Hall A
Additional information on DSM may be found by visiting their
website, www.dsm.com.
RXi's consumer health compounds are intended to affect the
appearance of the skin. As a consumer health product, no
preventative or therapeutic claims can be made. However,
these compounds may be developed more rapidly than therapeutics
and, therefore, the path to the market may be shorter and less
expensive.
Both posters will be available under the "Investors –
Presentations & Posters" section of the Company's
website, www.rxipharma.com approximately 1 hour following
each presentation.
About RXi's Proprietary Self-delivering RNAi (sd-rxRNA)
Technology Platform
RXi's proprietary sd-rxRNA technology has many advantages over
its competitors in the RNAi space. Scientists at RXi have
designed chemically-modified RNAi compounds with improved drug-like
properties that are potent, stable and specific. These
proprietary compounds have built-in delivery properties and
therefore do not require a delivery vehicle for local therapeutic
applications. The enhanced properties of sd-rxRNA
include: efficient spontaneous cellular uptake, stability,
reduced potential for immune stimulation, and potent, long-lasting
intracellular activity. All cell types tested (primary,
neuronal and non-adherent) internalize sd-rxRNA compounds uniformly
and efficiently, resulting in potent and long lasting
silencing. sd‑rxRNA compounds have the ability to selectively
block the expression of any target in the genome, thus providing
applicability to a broad spectrum of therapeutic areas.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage company developing innovative therapeutics that
address significant unmet medical needs. Building on the
pioneering discovery of RNAi, scientists at RXi have harnessed the
naturally occurring RNAi process which has the ability to "silence"
or down-regulate the expression of a specific gene that may be
overexpressed in a disease condition. RXi developed a robust
RNAi therapeutic platform including self-delivering RNA (sd-rxRNA)
compounds that have the ability to highly selectively block the
expression of any target in the genome, thus providing
applicability to many therapeutic areas. Our current programs
include dermatology, ophthalmology and cell-based
immunotherapy. RXi's extensive patent portfolio provides for
multiple product and business development opportunities across a
broad spectrum of therapeutic areas and we actively pursue research
collaborations, partnering and out-licensing opportunities with
academia and pharmaceutical companies. Additional information
may be found on the Company's website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-an-update-on-its-consumer-product-development-programs-at-the-society-for-investigative-dermatology-76th-annual-meeting-300442522.html
SOURCE RXi Pharmaceuticals Corporation